Gln3 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the Gln3 protein, a transcription factor in yeast (Saccharomyces cerevisiae). Gln3 is a key regulator of nitrogen metabolism and is part of the general amino acid control (GAAC) pathway, which orchestrates the expression of genes involved in nitrogen assimilation and amino acid biosynthesis. In normal conditions, Gln3 is tightly regulated by nutrient availability, cellular stress signals, and the TOR (Target of Rapamycin) signaling pathway. The inhibition of Gln3 typically disrupts its ability to translocate into the nucleus and bind DNA, effectively downregulating the expression of genes involved in nitrogen metabolism. This regulation is important for the yeast cell's adaptation to varying nitrogen sources, and compounds that inhibit Gln3 may therefore interfere with processes such as amino acid synthesis, nitrogen utilization, and cellular growth.
Structurally, Gln3 inhibitors may exhibit diversity but generally share properties that allow them to interfere with the activity, localization, or stability of the Gln3 protein. They may act by direct binding to the Gln3 transcription factor, altering its conformation, or modulating upstream signaling pathways that control Gln3 activation, such as the TOR pathway. By inhibiting Gln3, these compounds can impact the cellular metabolic network, revealing important aspects of nitrogen regulation and cellular response to nutrient availability. Due to their role in the modulation of the GAAC pathway, Gln3 inhibitors are valuable tools in studying nitrogen metabolism, gene regulation, and stress response mechanisms in yeast and potentially in other eukaryotes with similar regulatory networks. Such inhibitors have been instrumental in understanding the fine-tuned balance between nutrient signaling, metabolism, and gene expression in eukaryotic cells.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibitor of the Tor pathway; by inhibiting Tor, Rapamycin can indirectly reduce Gln3 activation. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
A direct TORC1 and TORC2 inhibitor, affecting pathways including Gln3-associated functions. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
TOR kinase inhibitor; can indirectly affect Gln3 activity via the Tor pathway inhibition. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
ATP-competitive inhibitor of mTOR; indirectly impacts Gln3 activity by modulating the mTOR pathway. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Inhibits both TORC1 and TORC2, potentially influencing Gln3-mediated transcriptional activity. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
Dual PI3K/mTOR inhibitor; by affecting mTOR activity, it may influence Gln3 function. | ||||||
WYE-687 | 1062161-90-3 | sc-364653 sc-364653A | 10 mg 50 mg | $235.00 $992.00 | ||
mTOR kinase inhibitor; can influence Gln3 indirectly via the mTOR pathway. | ||||||
WYE-354 | 1062169-56-5 | sc-364652 sc-364652A | 10 mg 50 mg | $286.00 $1200.00 | ||
Another mTOR kinase inhibitor; can impact Gln3 function by modulating the mTOR pathway. | ||||||
INK 128 | 1224844-38-5 | sc-364511 sc-364511A | 5 mg 50 mg | $321.00 $1835.00 | ||
Dual TORC1/2 inhibitor; has the potential to affect Gln3 activity. | ||||||
AZD2014 | 1009298-59-2 | sc-364420 | 5 mg | $303.00 | 2 | |
mTOR inhibitor; impacts Gln3 function by modulating the mTOR pathway. | ||||||